Statistiche di base
| LEI | 549300ZJ2JUDG0FI5Y49 |
| CIK | 1094038 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Marker Therapeutics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 26, 2025 |
Exhibit 99.1 Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 26, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 26, 2025 |
Exhibit 99.2 MARKER THERAPEUTICS CORPORATE PRESENTATION August 2025 NASDAQ: MRKR Forward Looking Statements Certain statements contained herein are forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, and Section 27 A of the Securities Act of 1933 , as amended, that involve risks and uncertainties . All statements other than statement |
|
| August 26, 2025 |
Exhibit 99.3 MARKER THERAPEUTICS CORPORATE PRESENTATION August 26, 2025 NASDAQ: MRKR Forward Looking Statements Certain statements contained herein are forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, and Section 27 A of the Securities Act of 1933 , as amended, that involve risks and uncertainties . All statements other than state |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2025 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THERAPEUT |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2025 |
Letter from Marcum LLP dated August 12, 2025. Exhibit 16.1 August 12, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Marker Therapeutics, Inc. under Item 4.01 of its Form 8-K dated August 7, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Marker Therapeutics, Inc. c |
|
| August 5, 2025 |
The date of this prospectus supplement is August 5, 2025. SELLING STOCKHOLDERS Filed pursuant to Rule 424(b)(7) Registration No. 333-228059 PROSPECTUS SUPPLEMENT NO. 2 (To prospectus dated November 16, 2018, and Prospectus Supplement No. 1 dated January 29, 2019) This Prospectus Supplement No. 2 supplements the prospectus dated November 16, 2018, as supplemented by Prospectus Supplement No. 1 dated January 29, 2019, included in a registration statement that we filed with the |
|
| June 17, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| June 17, 2025 |
Exhibit 99.1 Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma Houston, TX – June 17, 2025 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hemat |
|
| June 9, 2025 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 20, 2025 |
Exhibit 99.1 Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data read |
|
| May 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2025 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THERAPEU |
|
| April 24, 2025 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| March 31, 2025 |
Exhibit 19.1 Marker Therapeutics, Inc. Insider Trading Policy Effective November 17, 2023 Introduction This policy determines acceptable transactions in the securities of Marker Therapeutics, Inc. (the “Company”) by our employees, directors and consultants. During the course of your employment, directorship or consultancy with the Company, you may receive important information that is not yet publ |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37939 MARKE |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2025 |
Exhibit 99.1 Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & R |
|
| March 31, 2025 |
Exhibit 21.1 SUBSIDIARIES Marker Cell Therapy, Inc. GeneMax Pharmaceuticals, Inc. GeneMax Pharmaceuticals Canada, Inc. |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 21, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2025 (February 12, 2025) Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incor |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 12, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| February 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ De |
|
| February 4, 2025 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2025 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| January 17, 2025 |
Marker Therapeutics, Inc. 10,062,500 Shares of Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) Registration No. 333-284233 PROSPECTUS Marker Therapeutics, Inc. 10,062,500 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 10,062,500 shares of our common stock, by the selling stockholders identified in this prospectus under “Selling Stockholders”. Our shares of common stock covered by this prospectus |
|
| January 15, 2025 |
January 15, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| January 13, 2025 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| January 10, 2025 |
Filing Fee Table filed herewith Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Marker Therapeutics, Inc. |
|
| January 10, 2025 |
As filed with the Securities and Exchange Commission on January 10, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 10, 2025 Registration No. |
|
| December 23, 2024 |
Securities Purchase Agreement dated December 19, 2024 Exhibit 10.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 19, 2024, is by and among Marker Therapeutics, Inc., a Delaware corporation with offices located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77021 (the “Company”), and each of the investors signatory hereto (individually, a “Buyer” and collectively |
|
| December 23, 2024 |
Registration Rights dated December 19, 2024 Exhibit 10.2 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 19, 2024, is by and among Marker Therapeutics, Inc., a Delaware corporation with offices located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77021 (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECIT |
|
| December 23, 2024 |
EXHIBIT 2 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 23, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| December 23, 2024 |
EXHIBIT 1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Marker Therapeutics, Inc. |
|
| December 23, 2024 |
Form of Series A Warrant (Private Placement Warrant) Exhibit 4.2 [FORM OF SERIES A WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE R |
|
| December 23, 2024 |
Exhibit 4.1 [FORM OF SERIES B PREPAID WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFF |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 19, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| December 19, 2024 |
Securities Purchase Agreement dated December 19, 2024 Exhibit 10.1 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 19, 2024, is by and among Marker Therapeutics, Inc., a Delaware corporation with offices located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251, Houston, Texas 77054 (the “Company”), and each of the investors signatory hereto (individually, a “Buyer” and collectively |
|
| December 19, 2024 |
Exhibit 99.1 Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well tolerated in all study participants with no observation of immune-effector cell associated neurotoxicity |
|
| December 19, 2024 |
Exhibit 99.2 Marker Therapeutics Announces $16.1 Million Private Placement Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Houston, TX – December 19, 2024 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell- |
|
| December 17, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 17, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| December 17, 2024 |
Exhibit 99.1 Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer Houston, TX – December 17, 2024 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatmen |
|
| December 6, 2024 |
Up to $11,431,731 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-283512 PROSPECTUS SUPPLEMENT Up to $11,431,731 Shares of Common Stock We entered into an At The Market Offering Agreement, or the Sales Agreement, dated November 27, 2024, between us and H.C. Wainwright & Co., LLC, or the Sales Agent relating to the sale of shares of our common stock having an aggregate offering price of up |
|
| December 4, 2024 |
December 4, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| November 27, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 Marker Therapeutics, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Marker Therapeutics, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Marker Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized |
|
| November 27, 2024 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.3 Marker Therapeutics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 S |
|
| November 27, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 Marker Therapeutics, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Marker Therapeutics, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Marker Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized |
|
| November 27, 2024 |
Filing Fee Table filed herewith. Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) Marker Therapeutics, Inc. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
Exhibit 1.1 Marker Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) At The Market Offering Agreement November 27, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Marker Therapeutics, Inc., a Delaware corporation (the "Company"), confirms its agreement (this "Agreement") with H.C. Wainwright & Co., LLC (the "Agent"), as |
|
| November 27, 2024 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 Marker Therapeutics, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Marker Therapeutics, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Marker Therapeutics, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and exist |
|
| November 14, 2024 |
Exhibit 99.1 Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic cancer Houston, TX — November 14, 2024 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-s |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2024 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THER |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2024 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THERAPEUT |
|
| August 14, 2024 |
Exhibit 99.1 Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity syndrome (ICANS |
|
| August 12, 2024 |
Exhibit 99.1 Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma Houston, TX – August 12, 2024 – Marker Therapeutics, In |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| June 12, 2024 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 17, 2024 |
SC 13D/A 1 nea16-marker18847.htm NEW ENTERPRISE ASSOCIATES 16, L.P. / MARKER THERAPEUTICS, INC. - SCHEDULE 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Marker Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 57055L206 (CUSIP Number) Stephan |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
Exhibit 99.1 Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response nine months |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2024 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THERAPEU |
|
| April 26, 2024 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 8, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| April 8, 2024 |
Exhibit 99.1 Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study |
|
| March 26, 2024 |
Description of Securities of Marker Therapeutics, Inc. Exhibit 4.1 DESCRIPTION OF SECURITIES The following descriptions of the common stock of Marker Therapeutics, Inc., or the Company, Delaware law and certain provisions of the Company’s certificate of incorporation and bylaws are summaries. These summaries are qualified in the entirety by reference to the provisions of the Delaware General Corporation Law, or the DGCL, and the complete text of the C |
|
| March 26, 2024 |
Work Order #1 between Marker Therapeutics, Inc. and Cell Ready LLC dated February 22, 2024** Exhibit 10.9 Portions of this exhibit have been redacted pursuant to Item 601(b)(2) of Regulation S-K as (i) not material and (ii) likely to cause competitive harm if publicly disclosed. Omissions are designated as “****”. The Company hereby undertakes to furnish unredacted copies of this exhibit upon request by the Securities and Exchange Commission; provided, however, that the Company may reques |
|
| March 26, 2024 |
Exhibit 10.8 Portions of this exhibit have been redacted pursuant to Item 601(b)(2) of Regulation S-K as (i) not material and (ii) likely to cause competitive harm if publicly disclosed. Omissions are designated as “****”. The Company hereby undertakes to furnish unredacted copies of this exhibit upon request by the Securities and Exchange Commission; provided, however, that the Company may reques |
|
| March 26, 2024 |
Incentive Compensation Recoupment Policy Exhibit 97 MARKER THERAPEUTICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY EFFECTIVE NOVEMBER 17, 2023 1.INTRODUCTION The Board of Directors (the “Board”) of Marker Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37939 MARKE |
|
| March 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2024 |
Form of Common Stock Certificate of Marker Therapeutics, Inc. Exhibit 4.0 The Corporation shall furnish without charge to each stockholder who so requests a statement of the powers, designations, preferences and relative, participating, optional or other special rights of each class of stock of the Corporation or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Such requests shall be made to the Corporatio |
|
| March 26, 2024 |
Exhibit 21.1 SUBSIDIARIES Marker Cell Therapy, Inc. GeneMax Pharmaceuticals, Inc. GeneMax Pharmaceuticals Canada, Inc. |
|
| March 26, 2024 |
Exhibit 99.1 Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 29, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| January 8, 2024 |
Exhibit 99.1 Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple indications Marker provides updates supporting the clinical benefits of MT-401 in patients with measurabl |
|
| January 8, 2024 |
Exhibit 99.2 MARKER THERAPEUTICS CORPORATE PRESENTATION January 2024 Forward Looking Statements Certain statements contained herein are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, that involve risks and u |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2024 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| December 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 11, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| December 11, 2023 |
Exhibit 99.1 Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well and remains in complete response six months after MT-601 treatment Houston, TX – December 11, 2023 – Marker Therapeutics, Inc. (Nas |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 17, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| November 9, 2023 |
Exhibit 99.1 Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (zedenoleucel) for the treatment of |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THER |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 11, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commis |
|
| September 11, 2023 |
Exhibit 99.1 Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse Marker Therapeutics reports clinical updates in APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T cell therapy Patient with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy tolerated initial dose level well an |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2023 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THERAPEUT |
|
| August 14, 2023 |
Exhibit 99.1 Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive Officer and Monic Stuart, M.D., MPH, as Chief Medical Officer to spearhead Marker’s restructur |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2023 |
Exhibit 99.1 Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program Houston, TX – August 7, 2023 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indicati |
|
| July 10, 2023 |
Exhibit 99.1 European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients Houston, TX – July 10, 2023 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indicat |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 10, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| June 30, 2023 |
Unaudited Pro Forma Condensed Consolidated Financial Information Exhibit 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information On June 26, 2023 (the “Closing Date”), Marker Therapeutics, Inc. (the “Company”) completed the previously announced transaction with Cell Ready, LLC (“Cell Ready”) pursuant to a Purchase Agreement (the “Agreement), dated May 1, 2023, by and between the Company and Cell Ready. Pursuant to the Agreement, effective as of th |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| June 26, 2023 |
Exhibit 99.1 Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration Marker Therapeutics Awarded $2 Million Grant from NIH in Support of the Development of MT-401 for the Treatment of AML Patients Houston, TX – June 26, 2023 – Marker Therapeutics, Inc. (Nasdaq: MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on d |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 12, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| June 12, 2023 |
Exhibit 99.1 Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial Marker Therapeutics initiated APOLLO trial for the treatment of lymphoma patients who have relapsed after anti-CD19 CAR T therapy in the first quarter of 2023 Houston, TX — June 12, 2023 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on deve |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 31, 2023 |
Exhibit 99.1 Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells MT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro Houston, TX — May 31, 2023 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapie |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 31, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2023 |
Separation Agreement between Marker Therapeutics, Inc. and Peter Hoang dated as of April 27, 2023. Page 1 Exhibit 10.1 April 27, 2023 Peter L. Hoang 3787 Bissonnet St Houston , TX 77005 Dear Peter: This letter sets forth the substance of the separation agreement (the “Agreement”) that Marker Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be May l, 2023 (th |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2023 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THERAPEU |
|
| May 15, 2023 |
Purchase Agreement between Cell Ready, LLC and Marker Therapeutics, Inc., dated May 1, 2023 Exhibit 10.2 AGREEMENT This Agreement is entered into effective as of May 1, 2023 (“Effective Date”), by and between CELL READY, LLC, a Minnesota limited liability company (“Buyer”) and MARKER THERAPEUTICS, INC., a Delaware corporation (“Seller”). WHEREAS, Seller owns all of the equipment (“Equipment”) and leasehold improvements (“Leasehold Improvements”), in each case, located at (i) 4551 Kennedy |
|
| May 8, 2023 |
Exhibit 99.1 Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer Accomplished healthcare executive brings extensive drug development and regulatory experience from global pharmaceutical companies to Marker Therapeutics Houston, TX— May 8, 2023 – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-bas |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 1, 2023 |
Exhibit 99.1 MARKER THERAPEUTICS announces comprehensive non-dilutive AGREEMENT WITH CELLREADY™ STRUCTURED TO EXTEND MARKER’S FINANCIAL RUNWAY THROUGH YEAR-END 2025 MaRKER Announces LeADERSHIP TRANSITION & ProVIdes UPDATE ON OPERATIONAL STRATEGY HOUSTON, May 1, 2023 (GLOBE NEWSWIRE) - Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage company specializing in the development of next-generat |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 22, 2023 |
Exhibit 21.1 SUBSIDIARIES Marker Cell Therapy, Inc. GeneMax Pharmaceuticals, Inc. GeneMax Pharmaceuticals Canada, Inc. |
|
| March 22, 2023 |
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results Exhibit 99.1 Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results 2022 CLINICAL AND REGULATORY HIGHLIGHTS · Awarded $2 million grant from U.S. Food and Drug Administration (FDA) for the Phase 2 ARTEMIS trial of MT-401 in post-transplant acute myeloid leukemia (AML) · Investigational New Drug (IND) application cleared by FDA for multicenter Phase 1 trial of MT-601 for the tr |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 22, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 22, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258687 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement, each dated August 19, 2021) $9,868,603 Common Stock This prospectus supplement amends and supplements the information in our prospectus, dated August 19, 2021 (File No. 333-258687), or the Base Prospectus, and the shelf registration statement on Form S-3 of which the Prospec |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37939 MARKE |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 13, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)* Marker Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 57055L206 (CUSIP Number) Aisling C |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 26, 2023 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| January 26, 2023 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MARKER THERAPEUTICS, INC. Marker Therapeutics, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of this corporation is Marker Therapeutics, Inc., and the date on whi |
|
| January 3, 2023 |
Up to 25,770,990 Shares of Common Stock 424B3 1 tm2233325-3424b3.htm 424B3 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-268979 PROSPECTUS Up to 25,770,990 Shares of Common Stock This prospectus relates to the offer and sale of an aggregate of up to 25,770,990 shares of our common stock, $0.001 par value per share, by Lincoln Park Capital Fund, LLC (“Lincoln Park” or the “Selling Stockholder”). The shares inc |
|
| December 29, 2022 |
Marker Therapeutics, Inc. 4551 Kennedy Commerce Drive Houston, Texas 77032 CORRESP 1 filename1.htm Marker Therapeutics, Inc. 4551 Kennedy Commerce Drive Houston, Texas 77032 December 29, 2022 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Marker Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-268979 Ladies and Gentlemen: Marker Therapeutics, Inc. (the “Registrant” |
|
| December 23, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Marker Therapeutics, Inc. |
|
| December 23, 2022 |
As filed with the U.S. Securities and Exchange Commission on December 23, 2022. TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on December 23, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or orga |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 12, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| December 13, 2022 |
Exhibit 10.2 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 12, 2022, is entered into by and between MARKER THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein |
|
| December 13, 2022 |
Purchase Agreement, dated as of December 12, 2022, by and between the Company and Lincoln Park. Exhibit 10.1 EXECUTION COPY PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the "Agreement"), dated as of December 12, 2022, is made by and between MARKER THERAPEUTICS, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the "Investor"). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to s |
|
| December 13, 2022 |
Exhibit 99.1 Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million Houston, TX— December 13, 2022—Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, toda |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 22, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| November 22, 2022 |
Exhibit 99.1 Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer Houston, TX— November 22, 2022—Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tu |
|
| November 10, 2022 |
Exhibit 99.1 Marker Therapeutics Reports Q3 2022 Operating and Financial Results Company awarded $2 million U.S. FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of its lead T cell therapy candidate MT-401 in patients with post-transplant AML Houston, TX? November 10, 2022?Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development o |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2022 ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THER |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| September 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 22, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commis |
|
| September 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 13, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commis |
|
| September 13, 2022 |
EX-99.1 2 tm2225742d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML Award to fund clinical study of Marker’s multi-antigen targeted T cell therapy for the treatment of post-transplant AML patients with minimal residual disease Houston, TX—September 13, 2022—Marker Therapeutic |
|
| August 19, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 16, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2022 |
Marker Therapeutics, Inc. 2020 Equity Incentive Plan, as amended on May 24, 2022 Exhibit 4.4 Marker Therapeutics, Inc. 2020 Equity Incentive Plan Adopted by the Board of Directors: April 14, 2020 Approved by the Stockholders: May 19, 2020 Amended by the Board of Directors: April 5, 2022 Approved by the Stockholders: May 24, 2022 Table of Contents Page 1. General 1 2. Shares Subject to the Plan 1 3. Eligibility and Limitations 3 4. Options and Stock Appreciation Rights 4 5. Awa |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 11, 2022 |
Marker Therapeutics, Inc. 2020 Equity Incentive Plan, as amended Exhibit 10.2 ? MARKER THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN ? ADOPTED BY THE BOARD OF DIRECTORS: APRIL 14, 2020 APPROVED BY THE STOCKHOLDERS: MAY 19, 2020 AMENDED BY THE BOARD OF DIRECTORS: APRIL 5, 2022 APPROVED BY THE STOCKHOLDERS: MAY 24, 2022 ? ? ? TABLE OF CONTENTS ? ? ? ? ? ? Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 3 4. OPTIONS AND STOCK AP |
|
| August 11, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 11, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2022 |
Marker Therapeutics Reports Q2 2022 Operating and Financial Results Exhibit 99.1 Marker Therapeutics Reports Q2 2022 Operating and Financial Results Houston, TX? August 11, 2022?Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported fin |
|
| August 11, 2022 |
EX-FILING FEES 5 tm2223091d1ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 MARKER THERAPEUTICS, INC. Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 |
|
| August 4, 2022 |
Exhibit 99.1 Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023 Houston, TX?August 4, 2022?Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-g |
|
| August 4, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 27, 2022 |
Certificate of Amendment to Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MARKER THERAPEUTICS, INC. Marker Therapeutics, Inc. (the ?Company?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The name of this corporation is Marker Therapeutics, Inc., and the date on whi |
|
| May 13, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 13, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 13, 2022 |
RSU AWARD GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) ? Exhibit 10.1 ? MARKER THERAPEUTICS, INC. RSU AWARD GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Marker Therapeutics, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the |
|
| May 13, 2022 |
Exhibit 99.1 Marker Therapeutics Reports Q1 2022 Operating and Financial Results Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 Houston, TX?May 13, 2022?Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializ |
|
| April 26, 2022 |
MARKER THERAPEUTICS ANNOUNCES ENTRY INTO SERVICES AGREEMENT WITH WILSON WOLF Exhibit 99.1 MARKER THERAPEUTICS ANNOUNCES ENTRY INTO SERVICES AGREEMENT WITH WILSON WOLF HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) - - Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has en |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2022 MARKER THERAPEAUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37939 45-4497941 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 26, 2022 |
Exhibit 10.1 Binding Services Agreement (the ?Agreement?) between Wilson Wolf Manufacturing Corporation (?Wilson Wolf?) and Marker Therapeutics, Inc. (?Marker?) Dated April 21, 2022 Overview Gas permeable rapid expansion technology, commonly called G-Rex?, is a technology created by Wilson Wolf and routinely used throughout the field of cell therapy and gene-modified cell therapy for activation, t |
|
| April 15, 2022 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2022 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2022 MARKER THERAPEAUTICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37939 45-4497941 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 18, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-258687 PROSPECTUS SUPPLEMENT (To Prospectus and Prospectus Supplement, each dated August 19, 2021) $19,794,244 Common Stock This prospectus supplement amends and supplements the information in our prospectus, dated August 19, 2021 (File No. 333-258687), or the Base Prospectus, and the shelf registration statement on Form S-3 of which the Prospe |
|
| March 18, 2022 |
Exhibit 99.1 Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results Enrollment of first 20 patients of the Company?s Phase 2 acute myeloid leukemia (AML) trial completed in Q4 2021 Topline readout of Group 2 active disease anticipated in Q2 2022 Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023 Houston, TX?M |
|
| March 18, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 17, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
Exhibit 21.1 SUBSIDIARIES Marker Cell Therapy, Inc. GeneMax Pharmaceuticals, Inc. GeneMax Pharmaceuticals Canada, Inc. |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| February 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| February 16, 2022 |
Exhibit 99.1 Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion Results from safety lead-in stage of Marker?s Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, incr |
|
| January 20, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 19, 2022 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| January 20, 2022 |
Exhibit 99.1 Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Pancreatic Cancer Houston, TX ?January 19, 2022 ? Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indi |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 8, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| December 9, 2021 |
Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors Exhibit 99.1 Marker Therapeutics Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors Houston, TX ?December 9, 2021? Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appo |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2021 |
EX-99.1 2 tm2132397d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results Enrollment of first 20 patients of the Company’s Phase 2 AML trial anticipated in Q4 2021 Topline readout of Group 2 active disease anticipated in Q1 2022 Company to host year-end conference call and webcast in Q1 2022 Houston, TX—November 10, 2021—Marker Therape |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 19, 2021 |
Exhibit 99.1 Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas Houston, TX?August 19, 2021?Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announc |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 19, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 17, 2021 |
Marker Therapeutics, Inc. 3200 Southwest Freeway, Suite 2500 Houston, Texas 77027 Marker Therapeutics, Inc. 3200 Southwest Freeway, Suite 2500 Houston, Texas 77027 August 17, 2021 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren S. Hamill Re: Marker Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-258687) Request for Acceleration of Effective Date Ms. Hamill: In accordance |
|
| August 10, 2021 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.7 Marker Therapeutics, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of Marker Therapeutics, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this ?Agreement?), dated as of [?], between Marker Therapeutics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized |
|
| August 10, 2021 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 Marker Therapeutics, Inc. and , As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of Marker Therapeutics, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Marker Therapeutics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and exist |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2021 |
As filed with the Securities and Exchange Commission on August 10, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on August 10, 2021 Registration No. |
|
| August 10, 2021 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 Marker Therapeutics, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of Marker Therapeutics, Inc. Form of Preferred Stock Warrant Agreement This Preferred Stock Warrant Agreement (this ?Agreement?), dated as of [?], between Marker Therapeutics, Inc., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized |
|
| August 10, 2021 |
Form of Indenture, between the Registrant and one or more trustees to be named. Exhibit 4.3 Marker Therapeutics, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table Of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 S |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2021 |
? Exhibit 1.2 ? Execution Version? ? Marker Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) ? Controlled Equity OfferingSM ? Sales Agreement ? August 10, 2021 ? Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 ? and ? RBC Capital Markets 200 Vesey St., 9th Floor New York, NY 10281 ? Ladies and Gentlemen: ? Marker Therapeutics, Inc., a Delaware corporation (the ?Com |
|
| August 10, 2021 |
Exhibit 99.1 Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results Marker continues to enroll patients and activate clinical sites in Phase 2 AML trial following completion of safety lead-in Company?s new in-house cGMP manufacturing facility in Houston is fully operational Houston, TX?August 10, 2021?Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncolog |
|
| July 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 28, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| July 28, 2021 |
Exhibit 99.1 Marker Therapeutics Announces Opening of New cGMP Manufacturing Facility Facility is now available to manufacture study drug, MT-401, for Marker?s Phase 2 AML trial Houston, TX?July 28, 2021?Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological |
|
| July 6, 2021 |
Exhibit 99.1 Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML Company continues to enroll patients in main portion of the Phase 2 trial with topline data from active disease group expected in Q1 2022 Houston, TX?July 6, 2021?Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of |
|
| July 6, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 6, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| June 11, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 8, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 12, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 12, 2021 |
Exhibit 99.1 Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results Marker continues to advance Phase 2 AML trial, recently dosing first patient Company closed financing extending cash runway into Q1 2023 Company to host conference call and webcast today at 5:00 p.m. ET Houston, TX?May 12, 2021?Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology compan |
|
| May 5, 2021 |
? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2021 |
our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 23, 2021, TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2021 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 26, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Marker Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 57055L107 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842 |
|
| March 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A-1 Under the Securities Exchange Act of 1934 (Amendment No. 1) Marker Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 57055L 107 (CUSIP Number) Ann Leen 3200 Southwest Freeway, Suite 2500 Houston, Texas (713) 400-6400 (Name, Address and Telephone Number of Person |
|
| March 16, 2021 |
CORPORATE PRESENTATION March 2021 Exhibit 99.1 CORPORATE PRESENTATION March 2021 FORWARD LOOKING STATEMENTS Certain statements contained herein are forward - looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended , t hat involve risks and uncertainties. All |
|
| March 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 11, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 16, 2021 |
Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock Houston, TX ? March 12, 2021 ? Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the pricing of an und |
|
| March 16, 2021 |
Underwriting Agreement, dated March 11, 2021 Exhibit 1.1 28,572,000 Shares1 Marker Therapeutics, Inc. Common Stock PURCHASE AGREEMENT March 11, 2021 PIPER SANDLER & CO. As Representative of the several Underwriters named in Schedule I hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Marker Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to sell to the |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 13)* MARKER THERAPEUTICS, Inc. (Name of Issuer) COMMON STOCK, $0.0010 PAR VALUE PER SHARE (Title of Class of Securities) 57055L107 (CUSIP Number) William Sullivan, 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300 (Name, |
|
| March 15, 2021 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-232122 PROSPECTUS SUPPLEMENT (To Prospectus dated June 25, 2019) 28,572,000 Shares MARKER THERAPEUTICS, INC. Common Stock $1.75 per share We are offering 28,572,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the trading symbol ?MRKR.? On March 12, 2021, the last reported sale price of our common sto |
|
| March 15, 2021 |
EX-1 2 eclmrkr13daex1.htm JOINT FILING AGREEMENT CUSIP No. 57055L107 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree to the joint filing of Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock of Marker Therapeutics, Inc. The undersigned further agree and acknowledge that each shall be responsible for the timely filing of such amendments, and fo |
|
| March 11, 2021 |
The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| March 9, 2021 |
Exhibit 21.1 SUBSIDIARIES ? Marker Cell Therapy, Inc. ? GeneMax Pharmaceuticals, Inc. ? GeneMax Pharmaceuticals Canada, Inc. |
|
| March 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 9, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 9, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2021 |
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results Exhibit 99.1 Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results - Dosed first patient in the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia – - Completed construction of new in-house cGMP manufacturing facility in Houston to supply MultiTAA-specific T cell products, includ |
|
| March 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 3, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| March 3, 2021 |
Exhibit 99.1 Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant Topline readout of active disease group in AML trial expected in Q1 2022 Houston, TX – March 3, 2021– Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based i |
|
| January 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 13, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2021 |
Exhibit 99.1 Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates — Company expects to complete tech transfer and treat first patient with MT-401 manufactured in new cGMP facility in H1 2021 — Houston, TX – January 13, 2021 – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-onco |
|
| January 5, 2021 |
Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial Exhibit 99.1 Marker Therapeutics Announces FDA Lifted Partial Clinical Hold on Phase 2 AML Clinical Trial Houston, TX—January 5, 2021—Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U. |
|
| January 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 5, 2021 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| November 13, 2020 |
MRKR / Marker Therapeutics, Inc. / Eastern Capital LTD - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 12)* MARKER THERAPEUTICS, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 57055L107 (CUSIP Number) William Sullivan, 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300 (Name, |
|
| November 13, 2020 |
CUSIP No. 57055L107 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree to the joint filing of Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock of Marker Therapeutics, Inc. The undersigned further agree and acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the informatio |
|
| November 9, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2020 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2020 |
Exhibit 99.1 Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results - Initiated first Marker-sponsored study, a Phase 2 trial of MT-401 for the treatment of post-transplant acute myeloid leukemia, and enrolled the first patient in the safety lead-in portion - - Received alternate reagent and expect to submit required data to enable removal of partial clinical hold for IND f |
|
| November 9, 2020 |
Exhibit 10.2 MARKER THERAPEUTICS, INC. RSU AWARD GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Marker Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Com |
|
| November 9, 2020 |
Exhibit 10.1 MARKER THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2020 EQUITY INCENTIVE PLAN) Marker Therapeutics, Inc. (the “Company”), pursuant to its 2020 Equity Incentive Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and conditions as set forth here |
|
| November 9, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2020 ◻ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THER |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 10, 2020 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2020 |
Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results Exhibit 99.1 Marker Therapeutics Reports Second Quarter 2020 Operating and Financial Results Houston, TX—August 10, 2020—Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and re |
|
| August 10, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2020 ◻ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to . Commission File Number: 001-37939 MARKER THERAPEUT |
|
| June 30, 2020 |
Exhibit 99.1 Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates — Facility expected to be built by year-end, fully operational in 2021 — Houston, TX – June 30, 2020 – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell- |
|
| June 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 30, 2020 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| June 23, 2020 |
Exhibit 99.1 Marker Therapeutics Receives USAN Approval for “zelenoleucel” as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia Houston, TX – June 23, 2020 – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatmen |
|
| June 23, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 23, 2020 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission |
|
| June 18, 2020 |
EX-4 6 eclmrkr13dex4.htm EX 4 CUSIP No. 57055L107 Exhibit 4 Form of Certificate of Change filed Pursuant to NRS 78.209 (Incorporated herein by reference to Exhibit 3.1 to the Issuer’s Form 8-K filed with the U.S. Securities and Exchange Commission on September 15, 2016) |
|
| June 18, 2020 |
EX-3 5 eclmrkr13dex3.htm EX 3 CUSIP No. 57055L107 Exhibit 3 Form of Warrant Amendment Agreement (Incorporated herein by reference to Exhibit 10.3 to the Issuer’s Form 8-K filed with the U.S. Securities and Exchange Commission on August 11, 2016) |
|
| June 18, 2020 |
MRKR / Marker Therapeutics, Inc. / Eastern Capital LTD - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* MARKER THERAPEUTICS, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 57055L107 (CUSIP Number) William Sullivan, 10 Market Street, #773 Camana Bay Grand Cayman, KY1-9006 CAYMAN ISLANDS, 345-640-3300 (Name, |
|
| June 18, 2020 |
EX-2 3 eclmrkr13dex21.htm EX 2.1 CUSIP No. 57055L107 Exhibit 2.1 Form of Amended Series D-1 Warrant to Purchase Common Stock (Incorporated herein by reference to Exhibit 4.7 to the Issuer’s Form 8-K filed with the U.S. Securities and Exchange Commission on August 11, 2016) |
|
| June 18, 2020 |
CUSIP No. 57055L107 EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree to the joint filing of Schedule 13D (including any and all amendments thereto) with respect to the shares of common stock of Marker Therapeutics, Inc. The undersigned further agree and acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the informatio |
|
| June 18, 2020 |
EX-2 4 eclmrkr13dex22.htm EX 2.2 CUSIP No. 57055L107 Exhibit 2.2 Form of Series F-1 Warrant to Purchase Common Stock (Incorporated herein by reference to Exhibit 4.10 to the Issuer’s Form 8-K filed with the U.S. Securities and Exchange Commission on August 11, 2016) |
|
| June 12, 2020 |
As filed with the Securities and Exchange Commission on June 12, 2020 Registration No. |
|
| June 12, 2020 |
Marker Therapeutics, Inc. 2020 Equity Incentive Plan Appendix A MARKER THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 14, 2020 APPROVED BY THE STOCKHOLDERS: May 19, 2020 A-1 Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. ELIGIBILITY AND LIMITATIONS. 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS. 3 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. 6 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OT |
|
| June 1, 2020 |
Phase 1 Trial in Pancreatic Adenocarcinoma (TACTOPS) JUNE 1, 2020 Exhibit 99.1 Phase 1 Trial in Pancreatic Adenocarcinoma (TACTOPS) JUNE 1, 2020 FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of Marker Therapeutics, Inc. (“Marker,” “we,” “us,” “our” or the “C |
|
| June 1, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2020 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
|
| May 29, 2020 |
Exhibit 99.1 Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting — Results demonstrate potential of MultiTAA-specific T cell therapy in combination with chemotherapy as a first-line treatment option for patients with advanced or metastatic pancr |
|
| May 29, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 29, 2020 Date of Report (Date of earliest event reported) MARKER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37939 45-4497941 (State or other jurisdiction of incorporation) (Commission F |
